Pancreatic Cancer Research

Clinical trialPhase 1Completed

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)

Outcome
Results posted; primary outcome reported for one group, no comparison
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
13 May 2016
Ended
18 March 2020
Enrollment
47 participants
Sites
1
Primary outcomes
The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03
Sponsor type
Academic / other
Results posted
19 January 2022
Last update
25 July 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; primary outcome reported for one group, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 25 July 2022
DLT/MTD
The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03alisertib: Dose-Escalation of Alisertib and MLN0128: 30, n = 15TAK228: Dose-Escalation of Alisertib and MLN0128: 2, n = 15Values: mgTime frame: Up to 28 daysNo analysis posted for this outcome (outcome 1)
Participants
Dose Level 1: Alisertib 30 mg/MLN0128 1 mg: 3 started, 3 completedDose Level 2: Alisertib 30 mg/MLN0128 2 mg: 4 started, 4 completedDose Level 3: Alisertib 40 mg/MLN0128 2 mg: 7 started, 6 completedDose Level 4: Alisertib 40 mg/MLN0128 3 mg: 2 started, 2 completedDose-Expansion of Alisertib and MLN0128: Group 1: 10 started, 10 completedDose-Expansion of Alisertib and MLN0128: Group 2: 10 started, 9 completedPancreatic Cancer Cohort:: 11 started, 11 completed
Serious adverse events
Dose Level 1: Alisertib 30 mg/MLN0128 1 mg: 1 of 3Dose Level 2: Alisertib 30 mg/MLN0128 2 mg: 0 of 4Dose Level 3: Alisertib 40 mg/MLN0128 2 mg: 2 of 7Dose Level 4: Alisertib 40 mg/MLN0128 3 mg: 2 of 2Dose-Expansion of Alisertib and MLN0128: Group 1: 3 of 10Dose-Expansion of Alisertib and MLN0128: Group 2: 4 of 10Pancreatic Cohort: 6 of 11Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
The Safety Profile and Tolerability of the Combination of MLN0128 and Alisertib in Adult …
Dose Level 1: Alisertib 30 mg/MLN0128 1… 3/3; Dose Level 2: Alisertib 30 mg/MLN0128 2… 4/4; Dose Level 3: Alisertib 40 mg/MLN0128 2… 7/7; Dose Level 4: Alisertib 40 mg/MLN0128 3… 2/2; Dose-Expansion of Alisertib and MLN0128… 10/10; Dose Expansion of Alisertib and MLN0128… 10/10; Pancreatic Cancer Cohort 11/11 [Participants]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a phase Ib study designed to evaluate the safety and toxicity of the combination of Alisertib and MLN0128 in patients with advanced solid tumors with an expansion cohort in patients with previously treated metastatic TNBC.

Detailed description public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate the combination of Alisertib and MLN0128 in patients with advanced solid tumors refractory to standard treatment followed by an expansion cohort of patients with metastatic TNBC with exploratory correlative studies.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by the CTCAE v4.03 [Up to 28 days]. Number, mg. alisertib: Dose-Escalation of Alisertib and MLN0128 (n=15): 30. TAK228: Dose-Escalation of Alisertib and MLN0128 (n=15): 2.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

The Safety Profile and Tolerability of the Combination of MLN0128 and Alisertib in Adult Patients With Advanced Solid Tumors. [At least 30 days after the last dose of MLN0128 or alisertib]. Count Of Participants, Participants. Dose Level 1: Alisertib 30 mg/MLN0128 1 mg (n=3): 3; Dose Level 2: Alisertib 30 mg/MLN0128 2 mg (n=4): 4; Dose Level 3: Alisertib 40 mg/MLN0128 2 mg (n=7): 7; Dose Level 4: Alisertib 40 mg/MLN0128 3 mg (n=2): 2; Dose-Expansion of Alisertib and MLN0128: Group 1 (n=10): 10; Dose Expansion of Alisertib and MLN0128: Group 2 (n=10): 10; Pancreatic Cancer Cohort (n=11): 11.